Podcasts about Cart

With the arrival of the pandemic, and the implementation of lockdowns all around the world, investors and founders seized on the idea that this would permanently transform our lives - with a sharp focus on the way we shop and pay. The E-Commerce giants certainly agreed. Amazon's famous forecasting tool told them to build, build, build, and Shopify told investors they believed pandemic E-Commerce gains will stick because quote “convenience is habit-forming”. Venture capitalists followed, injecting $78b into E-Commerce companies in 2021 - and it was reflected in the hot stocks of that time - Afterpay, Peloton, Etsy. Three very different companies, but all pandemic powerhouses. Fast forward to 2022, this has all changed. Venture Capital funding for eCommerce is down 42% from the same period last year. Share prices have fallen, staff are being laid off, and companies are declaring bankruptcy. Today Sascha is joined by Mark Di Stefano, from The Information, to talk about his piece: Welcome to the E-Commerce Winter. Tell us what you think of The Dive - email us at thedive@equitymates.com Find out more, or follow us on social media here. In the spirit of reconciliation, Equity Mates Media and the hosts of The Dive acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people today. *****All information in this podcast is for education and entertainment purposes only. Equity Mates gives listeners access to information and educational content provided by a range of financial services professionals. It is not intended as a substitute for professional finance, legal or tax advice. The hosts of The Dive are not financial professionals and are not aware of your personal financial circumstances. Equity Mates Media does not operate under an Australian financial services licence and relies on the exemption available under the Corporations Act 2001 (Cth) in respect of any information or advice given.Before making any financial decisions you should read the Product Disclosure Statement and, if necessary, consult a licensed financial professional. Do not take financial advice from a podcast. For more information head to the disclaimer page on the Equity Mates website where you can find ASIC resources and find a registered financial professional near you. The Dive is part of the Acast Creator Network. See acast.com/privacy for privacy and opt-out information.

#1- A joke on the “woke”  #2- Have you taken the jab? Good luck, the clock is ticking… you've just reduced your lifespan  #3- More on the low Latin American IQ thing:  #4- It's the “Gringo Advantage“ NOT the gringo “take'' advantage #5- Do Latinos like us because we can do something for them or do they just like us as regular people? #6- Cart buying tips: What NOT to buy #7- Do you want to get into the exploding Crypto-currency world but don't feel quite confident enough to dive in? Our own Captain Mango has developed a unique one-on-one Crypto consulting and training service (he's been deep into crypto since 2013). To get started, email him at: bewarecaptainmango@gmail.com #8- Be sure to pick up my newly updated, "LATIN AMERICAN HEALTHCARE REPORT": The new edition for 2022 (and beyond) is available now, including the latest "Stem Cell Clinic" info and data and my top picks for the best treatment centers for expats and gringos. Just go to www.ExpatPlanB.com and click on the "Latin American Healthcare Report”.

This week on the podcast Agustin discusses the recent data release from CRISPR Therapeutics, Galapagos' CAR-T cell therapy acquisition, and the over-saturation of SCD therapies entering the market. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

A struggling jazz dancer joins up with two talented break dancers to form a street crew and gain legitimacy. Tune in as Chris talks B-boys, breakdancing, & Bolero - plus Peter Martin of @chunkmcbeefchest swings by in the sidecar as the LSCE screens the 1984 cult classic "Break-in'." Join Us! Check us out @lscep www.lscep.com Check out Peter Martin @ https://chunkmcbeefchest.com Works Cited: Canby, Vincent. “Film: Break-Dancing Stars.” The New York Times. May 5, 1984. Article Link. Accessed 4/29/22. Cart. “Film Reviews: Breakin'”Variety. May 9, 1984. Article Link. Accessed 6/20/22. Ebert, Roger. “Film Reviews: Breakin.'” Chicago Sun Times. May 9th, 1984. Article Link. Accessed 7/2/22 Gold, Richard. “Breakin' Stil at Lotsa Screens; Album Soars, Sequel in Works.” Variety. June 13, 1984. Article Link. Accessed 6/20/22. Hartley, Mark. Electric Boogaloo: The Wild, Untold Story of Cannon Films! 2014. Warner Bros. Pictures, 2014. 106 Mins. Medalia, Hilla. The Go-Go Boys: The Inside Story of Cannon Films. 2014. MVD Visual, 2021. Blu Ray. Trunick, Austin. Cannon Film Guide Volume 1: 1980-1984. Orlando, FL: Bear Manor Media, 2020. Vadukul, Alex. “Adolfo Quinones, and Early Star of Street Dance, Dies at 65.” The New York Times. Jan 13, 2021. Article Link. Accessed 4/28/22. Summers, Jimmy. “Review: Breakin.” Boxoffice. July 7, 1984. Article Link. Accessed 6/20/22. --- Send in a voice message: https://anchor.fm/lsce/message

Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.

Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.

Show note links: Join Lauren's subscription box masterclass ttps://bit.ly/subsmasterclass Join The Positive Pants Toolkit App & Community https://franexcell.com/positive-pants-toolkit-app Join The Mentorship https://beyondthedawnblog.com/the-mentorship/ Freebies: Grab your FREE ‘Stressed To Success' meditation: https://bit.ly/stressedtosuccess  Book in a free discovery call: https://calendly.com/franexcell/20min Ways to work with me: 1:1: https://franexcell.com/work-with-me SOS! (Success Over Stress) Group Programme (Coming back Spring 2022!) Join The Positive Pants Toolkit App & Community https://franexcell.com/positive-pants-toolkit-app The Mentorship 6 month programme: https://beyondthedawnblog.com/the-mentorship/ (Next Cohort June 2022) Products: Grab Your 365 day Gratitude Journal on Amazon:https://bit.ly/365daygratitude  Grab Your Positive Pants Firmly On Notebook:https://bit.ly/positivepantsonbook  To sign up for The Positive Pants Planner Waitlist: https://bit.ly/pppimwaiting  Contact: Make sure you're following me on Instagram https://www.instagram.com/imfranexcell/ and tag me into your key takeaways! Email me at hello@franexcell.com with any questions or take aways! For more, head over to: www.franexcell.com/ Why Self Care Isn't Selfish   Self care isn't selfish.    In my opinion, both through my training and my personal experience, it really is an essential piece of the puzzle of life and a huge game changer that isn't to be underestimated.   The term self care has become a bit ‘buzzy' which I feel often makes people roll their eyes and ignore it rather than sit up and go ‘oh, I should probably do that'.   Which is frustrating because usually the simplest things are often the things that could make the biggest difference.  But we don't trust it.  It seems ‘too simple' to have any real impact and that's simply not the case.   Why am I talking about this today?    By the time you're listening to this I shall be on a retreat. A retreat that's purely for me and only about my own rest, self care and nervous system care.    I will be doing yin yoga, drinking herbal tea, eating delicious balanced healthy food and listening to my body and what it needs.  For 5 days.  Yes, there's a hot tub…of course!   It's particularly important to look after your own wellbeing if you work with people on their mental or physical wellbeing.  Again, it's essential.  You can take on a lot and you're holding people in ways and spaces they've never been held before. You deal with a lot of emotion.  It's a huge responsibility.  But it means, in order for you to truly be able to show up as the best, most present version of you, you have to prioritise looking after yourself.   I do this on a daily basis, if you follow me on Instagram @imfranexcell you'll always see on my stories i'm either doing my ‘me mornings' i'm at the gym, in the pool, doing Heartmath, using my senate, all sorts of things that are about prioritising myself.   There's an underlying tone throughout society that to look after yourself is selfish and it's simply not true.   I really believe it's selfless.    It's also the key to unlocking more confidence, more self esteem, more calm, more self belief, more self love.     Fancy some of that?  I thought so.    When you DO start to put more of an emphasis on your own self care you might like to know what benefits it might have, apart from the obvious.    Looking after yourself and your own wellbeing is a pretty solid way to avoid burnout.  You don't want to get burned out.  It's not pretty.  Burn out happens at the point where your brain and body has had enough and it forces you to take action.  So instead of losing time to HAVING to rest you may as well out in a little time now so you can avoid having to.   Self care is not a time suck.  It's not something that is an annoyance on your to do list that TAKES time away from whatever else you want to be doing or are telling yourself you ‘should' be doing.  Self care will actively increase your productivity.     Every single time I do my work out, I take the time to be in the pool (on of mine and my nervous systems favourite things to do, I find being in the water incredibly regulating) I do my Heartmath or my meditation or use my sensate I have HUGELY increased levels of motivation, focus and productivity. I talk about this in my miracle ‘me' mornings episode from a few weeks ago.  It's a HUGE difference.  So if you're looking for your mojo and your motivation, it's being elusive to you.  Just give this a try.    It actively looks after your nervous system. You want your nervous system to be well looked after because it plays an essential part in your behaviour and, well, pretty much everything in your life.  A well looked after nervous system has a larger window of tolerance and capacity to cope with what life throws at you.  Your ability to recover from stress and triggers is bigger and quicker.  Your behaviour is far more conscious because you're not consistently operating from the emotional part of your brain and in fight, flight or freeze mode. Basically.  You want to look after your nervous system, which is what I'm doing this week.    It looks after your brain and your memory.  Your brain only has the ability to handle so much information in any one day.  When you prioritise self care you'll also probably find that you'll sleep better. Which means your brain has the time to recover, get to work on your healing and also make sure your memories are looked after too. Think about it, when you're tired and stressed out or have been burning the candle at both ends what happens to your memory?  Your ability to string a sentence together?  Your ability to problem solve? Your ability to cope with stressors?   You've got to think about what you're wiring into your brain in terms of thoughts, beliefs and behaviours. For the positive and the negative.  So when you don't look after yourself what could you be wiring in? That you're not worth the time? That you don't deserve it? That time spent on yourself is ‘wasted'?  That you're not important?   And what are you wiring in when you DO look after yourself?  That you ARE worthy?  That time invested in you is time well spent?  That you matter?  That you're important?    Like I said before, and when you think about what I've just said, looking after yourself is an incredible way to increase your self esteem and confidence.  For exactly the reasons I've just mentioned.    Think about who you need to show up for. Family? Friends? Clients? Making sure you're able to be the best version of yourself is so so important.  If you're psychologically and physically looking after yourself everyone around you benefits.    The other thing I really want you lovely rock star parents out there to think about is what you're modeling for your kiddos.  Think about where you may have learned to NOT look after yourself? What did you see or hear as a child around self care?  If we can create a generation of kids who look after themselves, their physical, emotional and mental health.  Imagine a world full of emotionally regulated and well rested individuals.  I mean, talk about a game changer.  Remember, as always, no judgement of yourself, only self compassion and curiosity.    You're not always going to get it right, this isn't about piling on pressure for yourself or another way for you to beat yourself up.  There are inevitably times when self care goes out the window because of time pressures, or things coming up that we aren't expecting.  But it's about making sure you have your plans to go back to it, know that it's important and knowing that you're worth the time too.    It's also remembering that self care isn't just bubble baths, yoga and massages. It's looking after your physical, emotional and mental health.It's remembering that all of these are linked. It's preventative in terms of the symptoms that can arise from both of those categories without adequate self care. Remember, if you get ill what happens to your business and the people you need to look after then?   It's getting more sleep.  It's drinking water. It's also setting boundaries, it's communicating your needs, to both yourself and other people. It's the way you talk to yourself.  It's the choices and decisions you make. It's not abandoning yourself.  It's noticing when your life is out of balance and choosing to do something about it. It's paying attention to yourself. It's self awareness.   Your self care is always going to look different to someone else's so there's no need to compare.    Self care in your business might look like acknowledging when something isn't working for you anymore.  Or that you've lost your joy.  Or that you need a change and actually allow yourself to go there.    That's why I'm excited about all the people doing Lauren's subscription box challenge because so many people are going to find a new way to ‘spark joy' in their business.  Me included.    I think subscription boxes are such a great way to inject some fun into your business.  It's a great business model where you get to shop for things you love, you get to give that joy to your subscribers every month AND you also get that sweet sweet recurring revenue that I'm always talking about.  So you know where you're at every month.  AND if you don't want to be a personal brand but know you want a business it's an incredible business model for that too.     Anyhoo…If you missed me talking about Lauren, she's a friend of mine and the absolute QUEEN of starting subscription boxes.  She's got 3 (nearly 4) of her own and she's grown them hugely in the last 18 months.  If you missed her challenge last week it's not too late, she's going to do a recap on her masterclass tonight (Monday 4th July 2022 that is)  If you haven't already signed up, it's tonight at 8pm UK. https://bit.ly/subsmasterclass She's also going to be talking about her amazing end to end programme ‘Tick all the boxes' which is everything you need to be able to set up and launch your subscription box from scratch.  She even teaches you ways that you don't have to front up the cash for the products too.  If now feels like the right time for you, and if you sign up with me, you'll also get access to all my bonuses too.    If you're in the first 5 people to buy you'll get to come spend the day with me at the very place I do a lot of the things i've been talking about today.  Eastwell Manor in Kent.  It's just an hour outside of London and my very own self care oasis.  It's a Champneys' spa hotel and I'm there at least 3x per week looking after myself in various ways.  We'll have afternoon tea together up at the manor and spend the day masterminding and taming mindset gremlins. Not only with me but with Lauren herself too.  I've promised her a go in the hot tub and she's very excited.    Even if you aren't in the first 5 you'll also get (on top of all of her bonuses) a 60 minute 1:1 with me, access to my Positive Pants Toolkit membership for 6 months (including the monthly group calls) and you'll get my Attitude of Gratitude chunky journal delivered to your door too.   Cart opens after the masterclass tonight and you'll be able to jump in and have me supporting you on your journey to being the owner of your very own subscription box.    So, bearing ALL of this in mind I want to leave you with one little thought.   Rest is not lazy.  Self care is not selfish. They are integral to your happiness and you deserve every minute of it.    Fx

The gang talks (almost) all things TV shows on this episode, including the always controversial Amazon Prime show "The Boys," the newest origin story show for "Ms. Marvel" and the much-anticipated Star Wars limited series "Obi-Wan Kenobi." SOUND OFF & send us a message with your thoughts about this episode - https://anchor.fm/givemikeamic/message Make sure to RATE, REVIEW & SUBSCRIBE to this podcast wherever you're listening at. Watch our video episodes over on YouTube - tiny.url/GiveMikeAMic Give Mike a "LIKE" over on Facebook, Instagram and Twitter. Check out curated book lists from all of your favorite hosts of the podcast over at https://bookshop.org/shop/GiveMikeAMic and if you see a book that catches your eye, click on the "Add to Cart" button & a portion of your purchase will go to raising money for local bookstores around the country that are struggling to keep in business. --- Send in a voice message: https://anchor.fm/givemikeamic/message Support this podcast: https://anchor.fm/givemikeamic/support

Jeannie hates flavor, I will land a double backflip or else I will feel shame, Cart narc parking lot fight, Sleep Paralysis is scary 

Bate papo com Ludmila Pontremolez, Co-Founder e CTO da Zippi, do satélite Hubble da NASA até cartão de crédito com pagamento semanal, uma história incrível de quem está promovendo mudanças essenciais para o mercado de Fintech, e como tudo isso beneficia diretamente aos profissionais autônomos e pequenos negócios.  Entre no grupo Papo Cloud Makers Roteiro do episódio em: papo.cloud/153 -------------------------------------------- Instagram / Twitter: @papocloud E-mail: contato@papo.cloud -------------------------------------------- Ficha técnica Direção e Produção: Vinicius Perrott Edição: Senhor A - editorsenhor-a.com.br Support the show: https://www.picpay.com/convite?@L7R7XH

Bem amigos do Bola Presa, mais um podcast no ar! gravam especialmente em uma sexta-feira (DE NOVO, mas juro que é temporário) para poder analisar as primeiras movimentações do período de Free Agency da NBA, que começa oficialmente no final da tarde desta quinta-feira (30). Tivemos não só contratações, como dramas e muitas trocas: Kevin Durant quer ir embora do Brooklyn Nets, Dejounte Murray é do Atlanta Hawks, Malcom Brogdon agora é do Boston Celtics e no meio do podcast até descobrimos que o Minnesota Timberwolves pagou tudo o que podia para ter Rudy Gobert. Que loucura! No Both Teams Played Hard respondemos perguntas sobre trapaça na pelada, Casimiro, sair de casa para ver amigos e violência nas escolas. ... |OS PARÇAS DO BOLA PRESA| MOMENTO ALURA: Ganhe R$100 de desconto na Alura em https://bit.ly/bolapresa_alura São mais de 1000 cursos em dezenas de áreas que podem te ajudar a CATAPULTAR sua carreira ASSINE O BOLA PRESA NO SPARKLE E RECEBA CONTEÚDO EXCLUSIVO - http://tiny.cc/BPSparkle São planos de R$14 e R$20 reais e mais de 80 podcasts para apoiadores Agora há opção de pagamento anual único via Pix, Boleto ou Cartão parcelado - http://tiny.cc/BPAnual O BOLA PRESA É PARCEIRO DA KTO Receba 20% de bônus no primeiro depósito com o cupom BOLAPRESA e faça suas apostas CONHEÇA AS NOVAS ESTAMPAS DA LOJINHA BOLA PRESA NA CAPHEAD - https://www.caphead.com.br/bolapresa/ ASSINE O UOL ESPORTE CLUBE E TENHA 7 DIAS GRÁTIS DO NBA LEAGUE PASS - tiny.cc/BPUOL ... NESTE EPISÓDIO Carinha do Jabá - 2:58 Durant quer ir embora - 6:18 Dejounte Murray no Hawks - 23:30 Brogdon e Gallinari no Celtics - 37:24 Warriors perde Gary Payton II e Otto Porter Jr - 43:22 Times em reconstrução - 48:00 Jalen Brunson no Knicks - 57:35 Mais contratações - 1:00:42 Momento Alura - 1:06:44 A troca de Rudy Gobert - 1:13:10 Maldição Bola Presa KTO - 1:22:57 Both Teams Played Hard - 1:25:26

SuChin Pak, journalist, producer, and cohost of the Add to Cart podcast, joins Jerry to share how the Pak family came to America, her career in journalism, and the journey from California to New York. Listen in as SuChin and Jerry talk about understanding representation in the media (and the lack thereof), the impact of being an Asian American newscaster on MTV before social media, and using your voice to speak out during difficult times. Buy SuChin's book, My Life Growing Up in Asian America, and listen to her podcast Add to Cart wherever you listen.Meet SuChinSuChin Pak is a veteran journalist who has been hosting and reporting the news for over 25 years. She has reported on ABC, NBC, Discovery Networks, Oxygen and E!. She is most known for her long career as the only female reporter for MTV News. From hosting red carpet shows, to reporting on presidential elections, international relief efforts and covering some of the biggest headlines in news, Pak has been a dedicated journalist since reporting on her first show at the age of 16.Connect with SuChinInstagram: https://www.instagram.com/suchinpak/?hl=enTwitter: https://twitter.com/suchinpak?lang=enWeb: https://lemonadamedia.com/show/addtocart/ Buy her book:My Life Going Up Asian In America: https://www.capeusa.org/my-life-growing-up-asian-in-americaThis episode of Dear Asian Americans is brought to you by the Quarter Pounder with Cheese from McDonald's. It's QPC time. Did your mouth just water? The QPC is the burger that breaks the norms of etiquette, the burger that napkins were made for, the burger that's saucy, drippy, oozing with flavor, always cooked when you order. So the next time you want a mouthwatering burger, order the QPC from McDonald's!// Support Dear Asian Americans:Merch: https://www.bonfire.com/store/dearasianamericans/Buy Me a Coffee: https://www.buymeacoffee.com/jerrywonLearn more about DAA Creator and Host Jerry Won:LinkedIn: https://www.linkedin.com/in/jerrywon/Instagram: https://www.instagram.com/jerryjwon/// Listen to Dear Asian Americans on all major platforms:Transistor.fm: http://www.dearasianamericans.comApple: https://apple.dearasianamericans.comSpotify: https://spotify.dearasianamericans.comStitcher: https://stitcher.dearasianamericans.comGoogle: https://google.dearasianamericans.com  Follow us on Instagram:  http://www.instagram.com/dearasianamericans Like us on Facebook: http://www.facebook.com/dearasianamericans Subscribe to our YouTube: http://www.youtube.com/dearasianamericans // Join the Asian Podcast Network:Web: https://asianpodcastnetwork.com/Facebook Group: https://www.facebook.com/groups/asianpodcastnetwork/Instagram: https://www.instagram.com/asianpodcastnetwork/Dear Asian Americans is produced by Just Like Media:Web: http://www.justlikemedia.comInstagram.com: http://www.instagram.com/justlikemedia

JJ and JP discuss a variety of topics including NIL, college football and how to become a millionaire as a cart girl.

I’m coming in just under the wire to get in on the fun of the Masters of VGM topic going around the video game music podcast community, but I made it! I hemmed and hawed over these picks quite a bit, and this list could have turned out differently depending on the day. That said, […]

O Nossa Economia aborda inovação no mercado financeiro: o chamado bitcoin. A jornalista Giane Guerra convidou o professor e sócio da CDI (Carteira do Investidor) Gabriel Fioravante para explicar o mundo das criptomoedas. O convidado também compara a função dos bancos com o dinheiro eletrônico, explica como investir com segurança e fala o que espera do futuro com a queda da moeda. Oferecimento: Sindilojas Porto Alegre e Cartórios de Protesto RS

In this week's episode we review a novel strategy for overcoming resistance to CAR T cell therapy that involves the dual targeting of myeloma cells and cancer-associated fibroblasts. We'll also explore a recent report demonstrating that loss of CCR4 expression is common after treatment of CTCL with the anti-CCR4 antibody mogamulizumab. Finally, we'll review real-world data demonstrating an association between corticosteroid exposure and risk of vaso-occlusive episodes in patients with sickle cell disease, providing further evidence that steroids should be avoided in this setting.

ImmunoACT CEO Dr Rahul Purwar outlines progress made by the firm's early-stage CAR-T therapy in India, which he believes can be available at a tenth of the price of current on-market treatments or around the cost range for bone marrow transplant. Laurus Labs, which holds about 27% in ImmunoACT, is expected to help shape the firm's globalization plans. https://scrip.pharmaintelligence.informa.com/SC146616/Whats-Next-At-Dr-Reddys-Biologics-CDMO-Cell-And-Gene-Therapy-Push https://scrip.pharmaintelligence.informa.com/SC125979/Early-Indian-Promise-For-A-Cut-Price-CAR-T-Therapy https://scrip.pharmaintelligence.informa.com/SC125879/Gene-And-Cell-Therapies-In-Asia-Indian-Environment-Evolving-But-Multiple-Issues-Unresolved https://scrip.pharmaintelligence.informa.com/SC144368/Dr-Reddys-Pilots-Sputnik-V-Soft-Launch-In-India-Explores-CART-Space

A man sells and buys things in old New England.

Basura y residuos no son lo mismo, los residuos son los desechos que generamos durante nuestras actividades diarias a partir del uso o consumo de diversos productos, la basura es la mezcla de todos esos residuos en un mismo lugar. Se debe realizar una separación básica y la razón es porque muchos de los inorgánicos […] La entrada RECICLADO DE PAPEL, PLÁSTICO Y CARTÓN – El Expresso de las 10 – Mi. 29 Jun 2022 se publicó primero en UDG TV.

In this episode, we are reminded that our relationship with God should be our primary concern!

This is the latest episode of the free DDW podcast, “The pursuit of better cancer treatments”. It covers two narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. They are called “The personal touch: the scientist making an impact in cancer research” and “Biotech's pursuit of next-generation CAR-T”.  In the first article, Lu Rahman speaks with Martyn Hiscox, uncovering his passion, dedication and the personal reason for developing cell therapy treatments for cancer. In the second article, Pierre-Louis Joffrin from Mogrify examines immunotherapies including an assessment of the next generation of stem cell derived products.  You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

On the latest BioCentury This Week podcast, a pair of deals demonstrates how Galapagos CEO Paul Stoffels is shifting the Belgian biotech's strategic focus from small molecules toward a diversified portfolio. Plus: why Friday's Supreme Court decision to overturn Roe v. Wade sets the stage for legal and legislative battles that could have broad implications for biopharma and how a new crop of Indian biotechs are seeking to offer dramatically cheaper CAR T therapies. This week's podcast is sponsored by the BioCentury-BayHelix East-West Summit 2022.

CAR T therapies are expanding as multiple myeloma treatment options. In addition to the two currently FDA approved CAR T therapies (Abecma and Carvykti) which use a patient's own T cells in a production process, new allo (off-the-shelf) options are being developed in clinical trials. Dr. Jesus Berdeja is one of the leading CAR T experts in multiple myeloma and in this episode, he will share the current development taking place for allo CAR T therapies. Join us to learn more about this exciting field in myeloma research which may provide faster and more availalble treatment options for patients.  Note: Myeloma Crowd Radio is becoming HealthTree Podcast for Multiple Myeloma. 

Dr. Rachna Shroff, of the University of Arizona Cancer Center, tells guest host, Dr. Shaalan Beg, of UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and Science 37, about advances in precision medicine for pancreatic cancer featured at the 2022 ASCO Annual Meeting. She also highlights compelling new data from the FOLFOX, FOENIX-CCA2, and HERB trials in hepatocellular carcinoma, cholangiocarcinoma, and biliary tract cancer.   TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News podcast. I'm Dr. Shaalan Beg, your guest host of the ASCO Daily News podcast today. I'm an adjunct associate professor at UT Southwestern Simmons Comprehensive Cancer Center and vice president of oncology at Science 37. I'm delighted to welcome Dr. Rachna Shroff, the associate dean for clinical and translational research and the chief of gastrointestinal (GI) medical oncology at the University of Arizona Cancer Center where she's also the interim chief of Hematology-Oncology. Dr. Shroff is also the chair-elect for the Gastrointestinal Cancer Symposium. Today we'll be discussing key abstracts in GI cancer that were featured at the 2022 ASCO Annual Meeting. Our full disclosures are available in the show notes and disclosures of all our guests on the podcast can be found on our transcripts at asco.org/podcasts. Dr. Shroff, thank you for being on the podcast today. Dr. Rachna Shroff: Thank you so much for having me. Dr. Shaalan Beg: Let's begin by reviewing what is new in the realm of precision medicine in GI cancers. One of the diseases where precision medicine has not made adequate inroads is pancreatic cancer. One of the most common mutations in pancreas cancer is KRAS, but there haven't been a lot of treatments that can target the most common forms of KRAS. What did we hear at ASCO22 regarding precision medicine and pancreatic cancer? Dr. Rachna Shroff: I agree, I think that the area of precision oncology is, unfortunately, lagging behind a little bit in pancreatic cancer. But I think as we have gotten better and better with our comprehensive genomic profiling, we are identifying subsets of patients within pancreas cancer who are potentially amenable to targeted therapies. You already mentioned KRAS mutations, and we obviously have a number of inhibitors in development in that space, though, we are still missing that key G12D mutation that we see in pancreas cancer. But what I think was really interesting that came out of ASCO22, was a lot of interest and emphasis on better understanding the KRAS wild-type patients in pancreatic cancer. Now, this is obviously a smaller subset of patients, given that the majority of patients have KRAS mutations. But there was a really interesting abstract, LBA4011, that looked at patients with locally advanced or metastatic pancreatic cancer, who were KRAS wild-type. They actually received gemcitabine in combination with a monoclonal antibody targeting EGFR and nimotuzumab. This was a study that was done entirely in Asia. It involved 92 Chinese patients that were randomly assigned to receive the combination of nimotuzumab with gemcitabine. What was interesting in this study is that the patients were found in the full analysis set to have a significantly longer median overall survival of 10.9 months versus 8.5 months with a hazard ratio of 0.5. So, that of course was intriguing and provocative for sure. Similarly, the other endpoints were also somewhat intriguing in terms of improvements in the median progression-free survival (PFS), etc. And specifically, patients without biliary obstruction had a longer PFS, which was an interesting finding as well. The nimotuzumab overall was pretty well tolerated and not any sort of surprising treatment-related adverse events (TRAEs) were noted. And so, this is definitely a drug that, I think, piques our interest in terms of being able to target patients with KRAS wild-type pancreatic cancer. I think that questions, however, that remain, and I think require further study is really understanding what this drug could do in combination with the chemotherapy combinations that we use more frequently in metastatic pancreatic cancers such as gemcitabine and paclitaxel or 5FU-based regimens like FOLFIRINOX. I think given that it is a relatively well-tolerated drug, it would be a very reasonable thing to investigate this drug further in the KRAS wild-type population with the kind of modern-day chemotherapy regimens that we use. And I think, of course, we all know that it is useful to be able to look at these types of drugs in a more global population. And so, a larger patient set I think would be very useful as well, but at least it tells us that there is a way to think about our KRAS wild-type patients with pancreas cancer and that perhaps we really need to understand and identify those patients' potential for precision oncology. Dr. Shaalan Beg: One of the GI cancers that has been a hotbed for precision medicine is cholangiocarcinoma, a disease that's very close to your heart. What updates did we hear at ASCO22 regarding cholangiocarcinoma and precision medicine? Dr. Rachna Shroff: This space of targeted therapy and cholangiocarcinoma has been incredibly exciting for the last few years and I think drug development has been rapid-fire in that space. The oldest, if you will, target that we've been thinking about for some time is the FGFR2 fusion patient population. And in Abstract 4009 by Dr. Goyal and colleagues, we saw the results of the FOENIX-CCA 2 trial which was looking at an oral FGFR inhibitor (futibatinib) in patients with intrahepatic cholangiocarcinoma, who harbor FGFR2 fusions and gene rearrangements. We had initially seen some of this data presented a few years back, but this was the updated data set. It was a single-arm phase 2 study that involved patients with advanced intrahepatic cholangiocarcinoma who had identified FGFR2 gene fusions, and they received futibatinib daily until progression. This was a traditional single-arm phase 2 study with a primary endpoint of overall response rate. At the final data cut, with a median follow-up of 25 months, there's actually a confirmed overall response rate of 41.7%. And I think that what was really exciting about this is this is a refractory patient population. So, in patients who have refractory cholangiocarcinoma, the other drugs, the non-targeted therapy drugs that we think through, really have response rates more in the single-digit to 10% range and so to have a confirmed overall response (OR) over 40% is truly exciting. The duration of the response was also exciting. This is not just a drug that works briefly, it has a duration of response of 9.5 months. And the mature median overall survival was 20 months. And in a disease which we talk about with the ABC-02 data of GemCis, a median OS in advanced disease of 11.7 months. This is really, really exciting for patients who harbor this fusion or gene rearrangement. We know that that's seen in about 10 to 15% of patients. So, again, we're dealing with a smaller subset, but it clearly demonstrates the need to identify FGFR2 gene fusions, so that we can offer these types of targeted therapies. This was not the first FGFR inhibitor that we have seen data on and in fact, we have 2 drugs already U.S. Food and Drug Administration (FDA) approved. And so, when we look at the common treatment-related adverse events that were identified with the futibatinib, there are really class effects related to FGFR inhibition like hyperphosphatemia, alopecia, dry mouth, nothing that really stood out or that was concerning. And so, I think this final analysis for the FOENIX study really just reaffirms the utility of futibatinib in patients with FGFR2 gene fusions, and the mature OS data, the duration of response, all of this really aligns with the need to identify patients with this alteration so that we can, post-gemcitabine based therapies, offer this targeted therapy or an FGFR inhibitor in general to these patients. I think the other really exciting abstract in the glandular carcinoma or biliary tract cancer space was Abstract 4006. This was the updated data from the HERB trial, which was an investigator-initiated multicenter phase 2 trial looking at trastuzumab deruxtecan (T-DXd) in patients who have HER2 expressing unresectable or recurrent biliary tract cancer. Trastuzumab deruxtecan, I'm sure everybody has been hearing about because it has been incredibly effective in HER2 alterations across a myriad of different disease sites. And so, not wanting to be left out, biliary tract cancers were investigated in this study with patients who had HER2 expression, so, that was HER2-positive IHC3+ or IHC2+/ISH+, and they also looked at HER2-low expressing patients, and [whose disease] were refractory or intolerant to gemcitabine-based therapy with the primary endpoint of overall response rate. So, in the HERB trial, a total of 32 patients were enrolled. 24 of them were HER2-positive and 8 were HER2-low and they all received trastuzumab deruxtecan. When you look at the efficacy data, the confirmed overall response rate in the patients with HER2-positive was 36.4%, which again, as I said, in a refractory patient population is certainly very exciting data. And the overall disease control median, PFS, and median OS were all pretty encouraging in terms of efficacy. What was also kind of intriguing was that there was some efficacy seen even in the patients who are HER2-low. Now, this is, in my opinion, a slightly less exciting amount of efficacy, but still important to note that the overall response rate in HER2-low was 12.5% with a median PFS that was also somewhat exciting at 4.2 months. And so, there is a potential clearly for targeting patients with HER2-high or HER2-positive with trastuzumab deruxtecan, and I think in the patients who are HER2-low, we need to better understand the potential utility. The common treatment-related adverse events that we see were the typical things that we've heard about with trastuzumab deruxtecan, but I think the one thing that was really worth noting was 8 patients or 25% of patients had interstitial lung disease (ILD), which we know is an important identified safety concern for patients who receive trastuzumab deruxtecan, and I think that's a pretty sizable number of 25%, so, I think that's going to really require a little bit more fleshing out for us to understand the safety for these patients. One question that a lot of us have had is whether these are patients who have received gemcitabine, which we know can also cause pneumonitis. And so, I don't know if we're seeing a higher percentage of ILD because of, 'priming' with prior gemcitabine. But regardless, I think this is just proof of principle that again, we need to identify patients with biliary tract cancers that have HER2-positivity because we now have a number of drugs including potentially trastuzamab deruxtecan to target [their disease] with after gemcitabine-based treatments Dr. Shaalan Beg: Absolutely. Any new biomarkers to keep on the radar for our listeners? Dr. Rachna Shroff: I think there are a lot of really exciting targets. One that was talked about and that we saw data on at ASCO [Annual Meeting] was from Abstract 4048, which looked at claudin [18]. Claudin is basically a transmembrane protein that kind of helps maintain the tight junctions between cells. In gastric cancer, in particular, we look at claudin 18 isoform 2, and there are 18.1 and 18.2 gene expressions that have been identified in gastric cancer. So, there was a very comprehensive abstract that was presented of over 1,900 samples that underwent comprehensive profiling by next-generation sequencing. And the patients were identified with claudin 18.1, and 18.2, high versus low. Claudin 18.2 expression was actually detected in 97% of the samples. It's slightly lower with claudin 18.1 at 63%. It's important to note that the primary tumors had higher expression levels than the metastatic tumors, so those were really the tumors in which they did a deeper dive. And in the process of doing this deeper dive, they did a really interesting kind of better understanding of the immune microenvironment and the immune profile in the samples that had claudin expression. And what was identified is that there was an inverse relationship basically between claudin 18.1 and 18.2 expression and correlation with PD-L1 positivity, tumor mutational burden (TMB)-high, M1 macrophages expression, NK cell presence, CD4 positive T-cells, myeloid dendritic cells. And so, there's clearly something between the presence of this claudin expression and the effect it has on the immune microenvironment. I think that's very relevant to keep in mind because as we all know, there's a whole space of drug development focused right now on anti-claudin 18.2 monoclonal antibodies, as well as a target for antibody-drug conjugates (ADC) and cellular therapies with CAR T-cell therapies being developed specifically against claudin 18. And so, understanding the immune microenvironment and the interaction between the claudin expression will be really important as we continue to charge forward in that space. Dr. Shaalan Beg: Absolutely. Very, very exciting. Sticking with the liver pancreas theme, what other studies piqued your interest with regards to hepatocellular carcinoma (HCC)? Dr. Rachna Shroff: It's a really exciting time in HCC. I mean, we actually have drugs that are working in the advanced space. And so, now there's a lot of interest in shifting to looking at preoperative neoadjuvant, and adjuvant approaches and what we can do to improve disease-free survival and overall survival in patients who are able to undergo prior resection. So, Abstract 4013 looked specifically at the efficacy and safety of adjuvant hepatic arterial infusion chemotherapy with FOLFOX. And this was a randomized open-label phase 3 trial. It actually included a total of 315 patients between 5 different centers and patients were randomly assigned to receive either 1 to 2 cycles of adjuvant HAIC FOLFOX (Hepatic Arterial Infusion Chemotherapy FOLFOX) versus just follow up, the control group had no adjuvant treatment, and the primary endpoint was disease-free survival here and in the intention to treat population, there was a significantly improved median disease-free survival at 27 months versus 11 months in the patients who were on the control arm. And there was a protocol analysis, there were a number of other efficacy endpoints including disease-free survival rates at 1, 2, and 3 years. And everything kind of leaned towards and or suggested an improvement with the utility of HAI FOLFOX in patients who undergo complete resection. It should be noted that this included patients specifically who had microvascular invasion on their resection. And so, these are patients who are at higher risk for recurrence as we know. This to me suggests that there could be a role for adjuvant treatment in patients who undergo complete resection with microvascular invasion (MVI). HAI is a very specific technique and it requires a highly skilled center in the placement of HAI pumps. And we're seeing more and more trials across the U.S. as well investigating the role of HAI in advanced disease and in perioperative approaches. And so, I think this is an area of much-needed continued research. There are, of course, a number of ongoing adjuvant studies looking at immunotherapy in the adjuvant setting. And so, it'll be really important to see how those read out and then to try to put all of these in context so that we can better understand local therapy like HAI FOLFOX versus more systemic adjuvant approaches like immunotherapy. Dr. Shaalan Beg: Thank you very much, Dr. Shroff for sharing your valuable insights with us. I really appreciate you taking the time to spend with us and our listeners. Dr. Rachna Shroff: Thanks so much. I enjoyed it. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. Finally, we'd really like to hear your feedback. If you could please take a moment to rate, review, and subscribe wherever you get your podcasts. Thank you very much!   Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Rachna Shroff: Consulting or Advisory Role: Exelixis, Merck, QED Therapeutics, Incyte, Astra Zeneca, Taiho Pharmaceutical, Boehringer Ingelheim, SERVIER, Genentech, Basilea Research Funding: Pieris Pharmaceuticals, Taiho Pharmaceutical, Merck, Exelixis, QED Therapeutics, Rafael Pharmaceuticals, Bristol-Myers Squibb, Bayer, Immunovaccine, Seagen, Novocure, Nucana, Loxo/Lilly, Faeth Therapeutics Disclaimer: The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Did Tom Cruise deliver on the sequel to his 1980s movie about jets and Navy propaganda? The guys review "Top Gun: Maverick" on this episode that has the need for speed! SOUND OFF & send us a message with your thoughts about this episode - https://anchor.fm/givemikeamic/message Make sure to RATE, REVIEW & SUBSCRIBE to this podcast wherever you're listening at. Watch our video episodes over on YouTube - tiny.url/GiveMikeAMic Give Mike a "LIKE" over on Facebook, Instagram and Twitter. Check out curated book lists from all of your favorite hosts of the podcast over at https://bookshop.org/shop/GiveMikeAMic and if you see a book that catches your eye, click on the "Add to Cart" button & a portion of your purchase will go to raising money for local bookstores around the country that are struggling to keep in business. --- Send in a voice message: https://anchor.fm/givemikeamic/message Support this podcast: https://anchor.fm/givemikeamic/support

Michael yells at a spoon. Harold is now known as Butt Lightyear. Listeners are leaving us messages. Alex got the virus. It's morbin' time! SOUND OFF & send us a message with your thoughts about this episode - https://anchor.fm/givemikeamic/message Make sure to RATE, REVIEW & SUBSCRIBE to this podcast wherever you're listening at. Watch our video episodes over on YouTube - tiny.url/GiveMikeAMic Give Mike a "LIKE" over on Facebook, Instagram and Twitter. Check out curated book lists from all of your favorite hosts of the podcast over at https://bookshop.org/shop/GiveMikeAMic and if you see a book that catches your eye, click on the "Add to Cart" button & a portion of your purchase will go to raising money for local bookstores around the country that are struggling to keep in business. --- Send in a voice message: https://anchor.fm/givemikeamic/message Support this podcast: https://anchor.fm/givemikeamic/support

Some real bad stuff happened yesterday. I don’t have a lot to say here, but hopefully this compilation I put together helps keep you fired up to do what needs to be done to get things back to at least where they were. I go over my feelings about the whole thing at the end, […]

Bem amigos do Bola Presa, mais um podcast no ar! Hoje gravamos especialmente em uma sexta-feira para discutir o Draft 2022 da NBA que aconteceu na noite de quinta (23). Falamos dos principais novatos, como Paolo Banchero, Chet Holmgren e Jabari Smith, das surpresas da noite e, claro, das trocas. Temos Jerami Grant no Portland Trail Blazers e DeAnthony Melton no Philadelphia 76ers. No Both Teams Played Hard respondemos perguntas sobre advogado com culpa, pé na bunda do romântico, vício em NBA, basquete de baixinhos e crescimento do esporte no Brasil. ... |OS PARÇAS DO BOLA PRESA| MOMENTO ALURA: Ganhe R$100 de desconto na Alura em https://bit.ly/bolapresa_alura São mais de 1000 cursos em dezenas de áreas que podem te ajudar a CATAPULTAR sua carreira ASSINE O BOLA PRESA NO SPARKLE E RECEBA CONTEÚDO EXCLUSIVO - http://tiny.cc/BPSparkle São planos de R$14 e R$20 reais e mais de 80 podcasts para apoiadores Agora há opção de pagamento anual único via Pix, Boleto ou Cartão parcelado - http://tiny.cc/BPAnual O BOLA PRESA É PARCEIRO DA KTO Receba 20% de bônus no primeiro depósito com o cupom BOLAPRESA e faça suas apostas CONHEÇA AS NOVAS ESTAMPAS DA LOJINHA BOLA PRESA NA CAPHEAD - https://www.caphead.com.br/bolapresa/ ASSINE O UOL ESPORTE CLUBE E TENHA 7 DIAS GRÁTIS DO NBA LEAGUE PASS - tiny.cc/BPUOL ... NESTE EPISÓDIO Carinha do Jabá - 3:14 Draft 2022 - 5:55 Momento Alura + Draft de Professores - 1:03:19 Mais Draft - 1:06:07 Maldição Bola Presa KTO - 1:17:14 Both Teams Played Hard - 1:22:16

Shamus Toomey, Editor in Chief and co-founder of Block Club Chicago, joined Bob Sirott to share the latest Chicago neighborhood stories. Shamus had details on: A Rogers Park Resident Has Sold Ice Cream On The Beach For Years. His Cart Broke — But Here's How You Can Help “I just love him so dearly and I just […]

Aquí estamos una quincena mas para hablaros de muchos juegos. En esta ocasión tenemos un viverito seguido de un estante lustroso con un buen puñado de fillers para que disfrutéis este veranito en la piscina. Fillers que no serán los de toda la vida (salvo alguna excepción). Ahí os va el menú: (4:17) El Pájaro Carpintero (15:15) El Vivero: (15:58) La Búsqueda del Planeta X (32:37) IKI (48:19) Estante Lustroso: (50:18) Picnic (56:55) Cartógrafos (1:02:59) Sushi Bar (1:08:05 Thief's Market (1:13:02) Rainbow (1:19:21) Mamma Mia (1:30:31) Red7 (1:38:29) High Score (1:42:28) Plata (1:48:18) K3

El cosmos es un lugar enorme y tenemos que es fácil perderse en él. Hacen falta expertos que lo conozcan en detalle y tracen mapas del firmamento como si fueran antiguos marinos. Hay cosmólogos que se dedican, en parte, a esos menesteres y, para ello, han desarrollado una serie de estrategias extremadamente sofisticadas.Para hablar sobre ello tenemos con nosotros a Laura Toribio San Cipriano. Laura es matemática y doctora en astrofísica. Realizó su tesis doctoral en el Instituto de Astrofísica de Canarias estudiando la composición química de regiones HII extragalácticas. Actualmente es investigadora postdoctoral en el CIEMAT donde trabaja en el grupo de cosmología. Además ha trabajado en el Observatorio del Teide como operadora de telescopios y ha hecho varias estancias de investigación en el instituto de astronomía de la UNAM en México. Combina su investigación con actividades de divulgación científica.

In this episode of Add To Cart, we checkout Becca Stern, the Co-founder of Mustard Made, the place to go for stylish, functional lockers. Yes, you heard me right, lockers…the essential high school backdrop in American coming of age movies. Becca's lockers have evolved into a range of shapes, sizes and colours…mustard being one of them of course. Back in the day, Becca had a habit of rescuing vintage lockers she spotted on the side of the road. This locker passion grew and grew and when Becca succeeded in convincing her sister to get in on the business, there was no stopping them. Now a multimillion dollar company, selling in Australia, the UK and US, Mustard Made is well and truly…well, made. Links from the episode:Who Gives A CrapCommon CircusA Book About Innocent by Dan GermainLocker Love: The Mustard Made Story | #173Questions answered in the podcast:What is the weirdest thing you've ever bought online? Who is your favourite retailer? Which retail fad do you wish was history?Can you recommend a book or podcast that our listeners should immediately get into? Finish this sentence. The future of retail is… This episode was brought to you by…eSuiteAbout your co-host: Becca Stern from Mustard MadeBecca is one half of Mustard Made and a mum to three boys. She is originally from London but now lives in Newcastle here in Australia. Mustard was born from the dream to work with her sister Jess and a need for really good storage for her home. The obsession with lockers and the style are inspired by her love for vintage furniture. She loves working for herself as it means she gets to do so many different things and that really suits her as a person.You can contact Becca at Mustard MadeAbout your host: Nathan Bush from eSuite Nathan Bush is a digital strategist, Co-founder of eCommerce talent agency, eSuite and host of the Add to Cart podcast. He has led eCommerce for businesses with revenue $100m+ and has been recognised as one of Australia's Top 50 People in eCommerce four years in a row. You can contact Nathan on LinkedIn, Twitter or via email.Please contact us if you: Want to come on board as an Add To Cart sponsor Are interested in joining Add To Cart as a co-host Have any feedback or suggestions on how to make Add To Cart betterEmail hello@addtocart.com.au We look forward to hearing from you! See acast.com/privacy for privacy and opt-out information.

A inflação está afetando cada vez mais o bolso dos brasileiros, mas como é estar entre a indústria e o consumidor? A jornalista Giane Guerra conversou com o supermercadista Bruno Lang para saber como as empresas estão lidando com a elevação dos preços de produtos. Durante o episódio eles também abordam a interferência da pandemia para a alta da inflação e as estratégias para manter um cliente no seu negócio. Oferecimento: Sindilojas Porto Alegre e Cartórios de Protesto RS

Guest: Kevin Lings | Chief Economist at Stanlib  See omnystudio.com/listener for privacy information.

Dr. Stephen Ansell, of the Mayo Clinic in Minnesota, tells host Dr. John Sweetenham, of the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, about ECHELON-1's compelling overall survival analysis in newly diagnosed Hodgkin lymphoma and key advances in the SHINE, MOMENTUM, and ASCEMBL trials that were featured at the 2022 ASCO Annual Meeting.   TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the associate director for Clinical Affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and host of the ASCO Daily News Podcast.  My guest today is Dr. Stephen Ansell, a professor and chair of medicine at the Department of Hematology at the Mayo Clinic in Minnesota. Dr. Ansell shares his insights on key advances in hematologic malignancies that were featured at the 2022 ASCO Annual Meeting.  Our full disclosures are available in the show notes and disclosures of all guests on podcasts can be found on our transcripts at asco.org/podcasts.   Stephen, it's great to have you on the podcast today.  Dr. Stephen Ansell: Thanks so much for having me, John.  Dr. John Sweetenham: So, Stephen, I'd like to start with your thoughts on Abstract 7503, which of course is one that you authored, and this is a 6-year follow-up study of the ECHELON-1 trial. This includes a positive overall survival analysis for brentuximab vedotin in newly diagnosed advanced Hodgkin lymphoma. Can you tell us more about this?  Dr. Stephen Ansell: Yeah, sure, John. And you know, as you point out, the thing that's really interesting and unique about this trial is we haven't had a lot of studies in Hodgkin lymphoma that show an overall survival advantage as you well know. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy has actually been quite difficult to beat when it's been an overall survival endpoint that one has been looking at.  There have been some other strategies in the past that have been looked at—the escalation of therapies such as escalator BEACOPP, and maybe modification of therapy to minimize toxicity, such as the RATHL trial where bleomycin is dropped out.  In all of these studies, there have been advantages for progression-free survival, but not clearly against ABVD as the standard and overall survival advantage. So, our listeners would probably know that ECHELON-1 was a comparison between brentuximab vedotin ABVD chemotherapy, and ABVD chemotherapy as the standard, showing an initially modified progression-free survival advantage and subsequently a progression-free survival advantage. But now with 6 years of follow-up, an overall survival advantage. And I think that's really what makes this quite unique.  Dr. John Sweetenham: One of the reasons I think many people, myself included, thought that it was going to be a very high bar to show an overall survival difference in this study was simply the fact that treatments to relapsed and refractory Hodgkin lymphoma, in general, have improved really quite substantially, both before and during the conduct of this trial.  Do you have any thoughts on that? Were you surprised? And any thoughts on why we're seeing this in the face of the rapidly evolving treatment landscape in the relapse setting?  Dr. Stephen Ansell: Yeah, I think that's an excellent point. And, John, I think there have been 2 schools of thought, as you know, those that have felt that the first shot was always the best one. And you should go hard right off the bat and others have said, you don't need to give everybody intensive treatment, because as you say, subsequent therapies can be very effective.  This would actually challenge that second position because when we looked at how patients were managed in both groups when they relapsed, the vast majority of relapsing patients in the group that got ABVD subsequently got brentuximab vedotin, as part of their regimen. Most patients—and it was balanced in both arms—got the standard kind of salvage treatment, autologous stem cell transplant approach, and some patients in both arms, got novel agents, including PD1 blockade, that was a minority, partly because of the timing of when the study was done.  But I think all of the things that we would normally do were done, and yet there's still a survival advantage. The one interesting thing I think that's worth taking away from this is when one looked at some of the influences on what might have made that overall survival difference, there were more patients progressing and dying from Hodgkin's in the ABVD arm suggesting that adding brentuximab vedotin does make a difference to the disease itself. But also interestingly, there were fewer patients in the brentuximab arm, who got a second lymphoma.  And interestingly, there were quite a substantial number of people in the ABVD arm when they relapsed to or subsequently got a different lymphoma, suggesting that the brentuximab vedotin, may actually target a precursor cell in a heme malignancies space and actually may have a benefit that way.  Dr. John Sweetenham: So, what's your overall conclusion from this study now that brentuximab vedotin plus ABVD is the standard of care for patients with newly diagnosed advanced Hodgkin lymphoma?  Dr. Stephen Ansell: I would say that if you have advanced-stage disease with classical Hodgkin lymphoma histology, it's very difficult not to say that this would be the standard of care to manage the patients.  I think we've learned that this study applied to older patients who are often difficult to treat. And so, hence, that's also a very valid treatment to give. And it's very difficult to argue against giving treatment that has an overall survival advantage for patients. So, in my practice, this has become the standard of care.  Dr. John Sweetenham: Okay, great. Thanks, Stephen. Let's move on and talk about LBA7502. This reported on the primary results of a double-blind placebo-controlled study known as SHINE, which looks at the use of ibrutinib in combination with bendamustine and rituximab followed by rituximab maintenance as a first-line treatment for older patients with mantle cell lymphoma. What are your thoughts and key takeaways from this study?  Dr. Stephen Ansell: Again, I think this is a very important study in older patients with mantle cell lymphoma. So, as you well know and many of our listening audience would know that we kind of has 2 strategies in mantle cell lymphoma. In younger patients, we may treat them with a more intense approach, sometimes with autologous stem cell transplant, often with a kind of alternating high-intensity therapies.  For patients who are older, bendamustine rituximab is really a standard therapy for patients with that demographic. And this now really pushes the field forward by showing that if you take bendamustine rituximab and add ibrutinib an effective therapy in the relapse setting, in the upfront setting, there is a substantial advantage for how patients do.  If one looks at the overall outcomes, it shows that progression-free survival is improved; we don't have overall survival benefit yet. But as we track these patients, it'll be interesting to see if that does transpire in time.  I will say again that I always like placebo-controlled arms because it helps us really get a handle on toxicities. And in general, in this population of patients, it was well tolerated. So, I think this, again, is a regimen that is going to be very useful in older patients.  Dr. John Sweetenham: I think that the lack of an overall survival benefit so far could of course be because there was a crossover in a study for those patients who progressed on the placebo-controlled arm.  But my other question about this, just to get your impression, is that there is a subgroup of elderly patients or older patients with a very slowly progressive disease where the management approach has been more of a watch-and-wait and observation-only approach until they become symptomatic. Do you think results like this, which start to show a progression-free survival benefit from upfront therapy, change that philosophy? Should we be thinking harder about whether anyone should be observed now?  Dr. Stephen Ansell: I think that's a good question. And to be frank, I will say that in my practice, I still have a spirit of, I'm happy to watch patients who have a very low burden of disease to just get a sense of the pace of the disease. Because as you say, you may be surprised by a subset of patients whom you may not need to treat for a year or even longer. And my view is that a year of no treatment is always better than a prolonged progression-free survival interval on treatment. So, I take the view that if you don't need to treat, that is still the best management.  Dr. John Sweetenham: Great, thank you! So, we're going to change gear for a moment and move out of lymphoid malignancy and talk a little about Myeloproliferative Syndrome. I'm interested to hear your thoughts on the MOMENTUM study. So, this was Abstract 7002, another phase 3 randomized study, in this case, looking at the use of momelotinib versus danazol in symptomatic and anemic patients with Myelofibrosis, who previously had a JAK inhibitor. What are your thoughts on this study?  Dr. Stephen Ansell: I think again, this is really good and very interesting data because those that treat Myelofibrosis will know these are challenging to treat. And many times, the symptoms they experience, the transfusion challenges they have, and the difficulty they have with very large spleens are all things that impact the quality of life quite profoundly. And therapies, in general, that would benefit those symptoms are always highly valuable.  So, I did find, again, I'm not as much of an expert in Myelofibrosis, but certainly, my colleagues who are were very satisfied with these results, basically showing improvement when compared to danazol, which again, I would anticipate as modest control with not particularly good efficacy, again, some of those symptoms I just spoke about, but momelotinib really showed a substantial benefit for the symptoms that this disease causes, and obviously transfusion requirements and improved spleen sizes and spleen symptoms.  So, I think in general, for managing patients for whom the quality of life is profoundly impacted, this is going to be a useful agent moving forward.  Dr. John Sweetenham: Okay, great. Thanks. And staying on the theme of Myeloid diseases, Abstract 7004 reported on the efficacy and safety, from the so-called ASCEMBL study, another phase 3 study, in this case, looking at the use of asciminib versus bosutinib in patients with Chronic Myeloid Leukemia (CML) who are in chronic phase, and who had already received 2 or more tyrosine kinase inhibitors. And this was an update at week 56 of the study. Why do you think this study should be on our radar?  Dr. Stephen Ansell: Well, I think again, we're always looking for agents that make a difference, particularly with subsequent lines of therapy in this disease. I think bosutinib is really regarded as a standard of care in this population of patients and an agent that comes along, ascitinib in this case, that shows a significant benefit, that really brings yet another tool for us to utilize in these patients.  I must say, again, as I looked at the results, comparing also looking for the major molecular responses, and the benefit and durability thereof, this was pretty impressive data. And so, I think it's very useful in this disease to have a plethora of tools that we can reach to be able to really impact the outcome of patients. So, I think, again, this is highly relevant data that we would use in the clinic in the not-distant future.  Dr. John Sweetenham: Do you think it's likely it'll move into frontline treatment over time?  Dr. Stephen Ansell: So, I think that is a good question. I don't know the answer to that, except to say that these results are pretty impressive. And so, I do believe that that's going to need to be tested, but as has been done in CML over the decades and which is really to be applauded, there have been randomized trials, comparing head-to-head agents showing which agent really has the greatest benefit and efficacy. So, I'll watch that space with a lot of interest.  Dr. John Sweetenham: Thanks! And finally, I'd like to return to lymphoid malignancy. In the 2020s, it would be almost impossible to review a meeting such as ASCO without saying something about CAR T-cell therapy, and this podcast is going to be no exception.  So, I wonder if I could get your thoughts on Abstract 7571. And this was an abstract, which reported real-world outcomes for axicabtagene ciloleucel, otherwise known as the Axi-Cel, for the treatment of large B-cell lymphoma. And it looked at the outcomes according to race and ethnicity. What are your thoughts on this study?  Dr. Stephen Ansell: Well, John, I smiled when you were said there's not a possible to really have a conversation without bringing in CAR T-cell somewhere along the way, but what I liked about this abstract, is it really was bringing in the real-world data, because many times and again, I have to stress that real-world data, when it comes to CAR T-cells is probably not the real world in the most real-world nature of things. And that is just you have to have access to certain centers to be able to get this therapy. And I think that's what this abstract actually points to.  It does look at almost 1,400 patients treated with Axi-Cel. And now that in large cell lymphoma, this is a standard of care where we either use a post-transplant and now even as a first relapse therapy, this is becoming highly relevant. And the question is just always seeing discrepancies between various population groups when we look at how outcomes transpire from this therapy.  And as it turns out, if one looks at Asian populations, those are really not adversely impacted, or Hispanic populations. But the African American population continues to have a less favorable outcome, even with this sophisticated therapy.  And that does suggest that possibly, when those patients, in general, can get access to this care, might actually be a little later in the disease, greater disease burden, possibly a little later line of therapy, resulting in not as favorable results.  I think this is whereas health care providers, we need to turn our attention in the future. And that is to say, how can we make care be equally good for all patients everywhere within our country, rather than there being nuggets where certain people benefit a lot and other areas where people benefit very little.  Dr. John Sweetenham: Yeah, thank you. There was good discussion after this study was presented and I think much of it focused around exactly what you've just said. Most of this difference is almost certainly not biological but it's really related to access to care and so on and that was an important take-home message. So, thanks for emphasizing that.  Stephen, thanks so much for sharing your insights with us today regarding the 2022 ASCO Annual Meeting on our podcast. I really appreciate your being willing to talk to us.  Dr. Stephen Ansell: John, thank you very much for having me.  Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstract discussed today on the transcripts of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.    Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Stephen Ansell:  Honoraria: WebMD, Research to Practice  Research Funding (Inst.): Bristol-Myers Squibb, Seattle Genetics, Affimed Therapeutics, Regeneron, Trillium Therapeutics, AI Therapeutics, ADC Therapeutics  Disclaimer:  The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.       

Racer to Racer Podcast Presented by Race 92 - In this episode we chat with Chris Kneifel. Chris Drove in the 1983 and 1984 Indianapolis 500s. He raced Sports Cars, competing in TransAm and winning the 2001 24 Hours of Daytona. He was also the Race Director for CART from 2001-2004. Buy Race 92 and Podcast merch at www.race92.com! https://anchor.fm/racer-to-racer AUDIO TRACK: Into The Twilight - AMG

This week Megan and Beau dive back into the Dune Encyclopedia to talk Leto's special pets the D Wolves while Beau confuses everyone with an entry on Leto's special suspensor cart. If anyone ever drew an anatomically correct drawing of the God Emperor, we hope we never see it.  This episode's theme song is Short Stories from Vendla. Find them over on Epidemic Sound.  Podcast art by Josh Hollis

Wildfire season runs almost all-year round in the West, and CalMatters.org's Pulitzer Prize-winning reporter Julie Cart examines the compelling stories of several firefighters who give up any sense of a normal family life to help save people's lives and homes. The Morning Show with Nikki Medoro talks with Cart about the help that's needed for these human beings who have sacrificed so much. See omnystudio.com/listener for privacy information.

Wildfire season runs almost all-year round in the West, and CalMatters.org's Pulitzer Prize-winning reporter Julie Cart examines the compelling stories of several firefighters who give up any sense of a normal family life to help save people's lives and homes. The Morning Show with Nikki Medoro talks with Cart about the help that's needed for these human beings who have sacrificed so much. See omnystudio.com/listener for privacy information.

Today we dig into the latest LaBrant Family insanity, the Cart Narc calls in, we discuss thirst traps in all their various forms (including sexy wood chopping), discuss Drake's new album/Zach debuts a Drake collab, and much more!

This month's GACC brings you a scaly sex toy, a dramatic phone rescue, Satan's socks, lots of remains, two piping plovers, and one way to gaslight your neighbors. Tune in for Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors/

SHOW NOTES 01:50 The first perovskite solar cell with a commercially viable lifetime is here | Interesting Engineering  A team of researchers from Princeton University has built the first perovskite solar cells that last long enough to be commercially viable.Silicon-based cells, which many regard as an expensive and suboptimal component, have dominated the renewable energy market since their introduction in 1954. This new technology, which is not only incredibly durable but also meets common efficiency standards, has the potential to change that. Expected to outperform industry norms for roughly 30 years, well beyond the 20-year criterion for solar cell viability Perovskite solar cells are regarded as high-efficiency, low-cost modular technology for implementation in the renewable power industry. Less Energy = Less $$$ Would become more fragile in that case The name “perovskite” comes from the nickname for their crystal structure. Can be manufactured at room temperature, which means they need less energy than manufacturing silicon.  Can be modified to be flexible and transparent The new device created by these researchers estimated lifetime is a five-fold increase over the previous record, which was established by a lower efficiency perovskite solar cell in 2017. Additionally they created a new testing method allowing them to test the longevity of these particular types of solar cells. Ranging from a regular summer day's baseline temperature to an extreme of 230 degrees Fahrenheit (110 degrees Celsius). “accelerated aging technique” Chose four aging temperatures and measured outcomes over four independent data streams. Overall, they found that the device will run at or above 80 percent of its peak efficiency under continuous illumination for at least five years.According to the researchers, that is the equivalent of 30 years of outdoor operation in a city like Princeton, New Jersey.  Joseph Berry, a senior fellow at the National Renewable Energy Laboratory who was not involved in the study, said:“This paper is likely going to be a prototype for anyone looking to analyze performance at the intersection of efficiency and stability … By producing a prototype to study stability, and showing what can be extrapolated [through accelerated testing], it's doing the work everyone wants to see before we start field testing at scale. It allows you to project in a way that's really impressive."   07:36 Immunotherapy booster produces 10,000 times more cancer-fighting cells | New Atlas Researchers at Washington University in St. Louis have found that adding a booster protein can significantly improve the outcome of cancer immunotherapy.The research showed the protein produced 10,000 times more immune cells in mice, and all mice survived the entire experiment. We are talking about  CAR T cell immunotherapy, which is a promising new treatment where doctors extract T cells from a patient, genetically engineer them to target specific cancer cells, and return them to the body to hunt those cells down.  The effectiveness can start to drop over time. In the new study, the scientists investigated ways to combat this problem by boosting the number of T cells. Doesn't naturally stick around very long, so the researchers modified it to circulate in the body for weeks. They turned to a protein called interleukin-7 (IL-7), which the body naturally expresses to ramp up T cell production in the event of illness. The team tested this longer-lasting IL-7 in mouse models of lymphoma, administering the protein on various days after the initial CAR T cell injection.3 groups: 1.) Control (no immunotherapy), 2.) Received CAR T cell therapy without IL-7, and 3.) with IL-7 John DiPersio, senior author of the study, talks on the findings:“When we give a long-acting type of IL-7 to tumor-bearing immunodeficient mice soon after CAR T cell treatment, we see a dramatic expansion of these CAR-T cells greater than ten-thousandfold compared to mice not receiving IL-7 … These CAR T cells also persist longer and show dramatically increased anti-tumor activity.” Every mouse that received CAR T cell therapy and IL-7 survived the entire 175 days of the experiment, with their tumors shrinking to the point of being undetectable by day 35. In contrast, mice that received immunotherapy alone survived just 30 days on average. Human clinical trials of IL-7-boosted CAR T cell therapy are set to begin soon in patients with a type of lymphoma.   12:29 Study identifies receptor that could alleviate need for chemo, radiation pre-T cell therapy | ScienceDaily   Before a patient can undergo T cell therapy designed to target cancerous tumors, the patient's entire immune system must be destroyed with chemotherapy or radiation.Reducing your immune cells helps the transferred T cells to be more effective.  Toxic Side Effects: nausea, extreme fatigue and hair loss. Now a research team ,a collaboration between scientists from UCLA, Stanford and the University of Pennsylvania, has shown that a synthetic IL-9 receptor allows those cancer-fighting T cells to do their work without the need for chemo or radiation. Christopher Garcia, PhD, at Stanford, talks on these T cells:“When T cells are signaling through the synthetic IL-9 receptor, they gain new functions that help them not only outcompete the existing immune system but also kill cancer cells more efficiently … I have a patient right now struggling through toxic chemotherapy just to wipe out his existing immune system so T cell therapy can have a fighting chance. But with this technology you might give T cell therapy without having to wipe out the immune system beforehand." Imagine being able to receive this treatment without destroying your whole body. The body would be in a much better position to fight off any other outside problem. Antoni Ribas, MD, PhD, a senior investigator on the study, believes this finding, “opens a door for us to be able to give T cells a lot like we give a blood transfusion." Back in 2018 a set of researchers found that a synthetic cell growth cytokine could be used to stimulate T cells engineered with a matching synthetic receptor. With this system, T cells can be manipulated even after they have been given to a patient. But they were looking at IL-2 back then, but now they started investigating IL-9. The synthetic IL-9 signal made T cells take on a unique mix of both stem-cell and killer-like qualities that made them more robust in fighting tumors. According to the researchers, "In one of our cancer models, we cured over half the mice that were treated with the synthetic IL-9 receptor T cells."Proved to be effective in multiple systems The process worked whether they gave the cytokine to the whole mouse or directly to the tumor   17:34 Astronomers Unveil The Most Detailed Map of The Metal Asteroid Psyche Yet | ScienceAlert  The asteroid Psyche is especially interesting, and NASA is sending a mission to investigate the unusual chunk of rock.In advance of that mission, a team of researchers combined observations of Psyche from an array of telescopes and constructed a map of the asteroid's surface. Psyche (16 Psyche) is an M-type asteroid, which is the rarest type of asteroid and makes up about 8 percent of known asteroids.Contain more metal than the other asteroid types, and scientists think they're the source of iron meteorites that fall to Earth. Called a dwarf planet because it's about 220 kilometers (140 mi) in diameter.  Psyche is sometimes called the 'Gold-mine asteroid' because of the wealth of iron and nickel it contains NASA wants to take a closer look at the asteroid.The mission is called Psyche and is scheduled for launch sometime in fall 2022.  The spacecraft will rely on solar-electric propulsion and a gravity-assist maneuver with Mars to arrive at Psyche in 2026. It'll spend 21 months studying the asteroid and will follow four separate orbital paths, each successive one closer than the previous. A team of researchers constructed a new map of Psyche's surface to help prepare for the mission.  Saverio Cambioni from MIT's Department of Earth said in a press release:“Psyche's surface is very heterogeneous … It's an evolved surface, and these maps confirm that metal-rich asteroids are interesting enigmatic worlds. It's another reason to look forward to the Psyche mission going to the asteroid." The new map is based on two types of measurements. Pure iron has an infinite dielectric constant.  One is thermal inertia, which is how long a material takes to reach the temperature of its environment. Higher thermal inertia means it takes longer. The second is the dielectric constant. The dielectric constant describes how well a material conducts heat, electricity, or sound. A material with a low dielectric constant conducts poorly and is a good insulator and vice versa. Combining thermal inertia and dielectric constant measurements gives a good idea of which surface regions on Psyche are rich in iron and other metals. Overall, the study shows that 16 Psyche's surface is covered in a large variety of materials. It also adds to other evidence showing that the asteroid is metal-rich, though the abundance of metals and silicates varies significantly in different regions.   22:39 World's most efficient passenger plane gets hydrogen powertrain | New Atlas  The Celera 500L is a remarkable design, and according to the company behind it, Otto Aviation, its odd shape delivers an astonishing 59 percent reduction in drag, and a massive leap in efficiency and range compared to traditional plane geometries. Otto claims the Celera 500L in standard fossil fuel-propelled form is "the most fuel-efficient, commercially viable business aircraft in the world."The whole thing is designed to maximize laminar flow – smooth layers of airflow with little to no mixing of adjacent layers moving at different speeds. Trying to avoid the swirls and eddies that lead to air turbulence at speed, causing aerodynamic drag and wasted energy. The company states that it uses 80 percent less fuel than a traditional design. Running on an efficient 550-horsepower combustion engine, Otto claims this thing will fly six passengers up to 4,500 nautical miles (8,334 km) at cruise speeds over 460 mph (740 km/h), challenging small business jets for top speed while more than doubling their range.A glide ratio of 22:1 allows pilots to switch off the engine altogether and glide for up to 120 miles (200 km) completely unpowered. Now the rich people who fly around in their CO2 producing private jets can make a change…will they? Otto has built a full-scale prototype, and by November last year the company announced it had completed some 55 successful test flights, reaching speeds over 250 mph (400 km/h) and altitudes up to 15,000 ft, and that "all test flights have validated the aircraft's operating performance goals." Otto has now announced a collaboration with hydrogen aviation pioneers ZeroAvia to develop a fuel cell-electric powertrain specific to the Celera's requirements.The shape works well with a hydrogen concept – hydrogen powertrains can weigh much less than battery-electric ones, but they tend to take up a bit of space. ZeroAvia is being relatively humble with its ambitions to begin with, aiming for a range of just 1,000 nautical miles (1,852 km) of zero-emissions range for a hydrogen-fueled Celera. Founder and CEO of ZeroAvia, Val Miftakhov, said in a press release:“The majority of our commercial deals to date have focused on retrofit and line-fit for existing airframes, which is essential to deliver zero-emission flight to market as quickly as possible. However, efficiency gains from new airframe design can expand the impact of zero-emission aviation. We are pleased to collaborate with innovators, like Otto Aviation, bringing cutting-edge clean sheet designs to market as we can optimize the hydrogen-electric propulsion system for those designs.” Otto has already shown it can complete successful flights of their fossil fuel plane, but we will wait and see how this partnership pans out.

La misión espacial europea Gaia está trazando el mapa más detallado de la Vía Láctea. La última entrega ofrece datos de casi 2.000 millones de estrellas de nuestra galaxia y descubrimientos sorprendentes como terremotos estelares y astros desconocidos. Hemos entrevistado a la astrofísica Rocío Guerra, responsable de las operaciones científicas del observatorio. Les hemos informado de los resultados esperanzadores de un medicamento de inmunoterapia CAR-T contra el linfoma desarrollado íntegramente en el Hospital de Sant Pau de Barcelona. En un ensayo en fase 1 se ha revelado eficaz en cinco de los diez pacientes tratados. Con testimonio de Javier Briones, responsable científico del proyecto. Enrique Sacristán nos ha informado de un estudio que sitúa en el actual Kirguistán el origen de la mayor pandemia de la historia, la peste negra que asoló la Europa medieval en el siglo XV. Álvaro Martínez del Pozo nos ha hablado de Alfa-gal, un carbohidrato presente en los mamíferos, excepto los humanos y resto de primates. Este disacárido es responsable de un tipo de alergia alimentaria a la carne roja y otros productos derivados y también del rechazo a los xenotrasplantes o trasplantes de órganos procedentes de animales como el cerdo. Con Jesús Puerta hemos conocido Medipix, una familia de detectores de píxeles de conteo de fotones y seguimiento de partículas desarrollados por una colaboración internacional, organizada por el CERN, y con aplicaciones en campos tan variados como la salud o la autentificación de obras de arte. José Luis Trejo nos ha informado de los procesos cerebrales, sensoriales y motrices involucrados en una cata de vino. La Antártida es un continente helado, inhóspito, pero como nos ha contado Javier Cacho, eso no ha impedido que se haya intentado desarrollar cultivos para alimentar a los exploradores y científicos, y como ensayos para la colonización de otros mundos. En nuestros “Destinos con ciencia”, Esther García nos ha llevado de visita al museo oceanográfico de Mónaco Escuchar audio

Bem amigos do Bola Presa, mais um podcast no ar! Hoje discutimos título do Golden State Warriors, que bateu o Boston Celtics três vezes seguidas e se sagrou CAMPEÃO da NBA mais uma vez. Alguns dos títulos do Warriors já pareceram inevitáveis, esse foi bem diferente. Discutiremos a trajetória do time, o que deu certo e os riscos que tomaram. Também iremos nos despedir do Celtics, que teve uma temporada histórica antes da frustração dos jogos finais. Também gastaremos algum tempinho para falar do negócio (já?!) que mandou Christian Wood do Houston Rockets para o Dallas Mavericks em troca de Boban Marjanovic e outros jogadores menos carismáticos. ... |OS PARÇAS DO BOLA PRESA| MOMENTO ALURA: Ganhe R$100 de desconto na Alura em https://bit.ly/bolapresa_alura São mais de 1000 cursos em dezenas de áreas que podem te ajudar a CATAPULTAR sua carreira ASSINE O BOLA PRESA NO SPARKLE E RECEBA CONTEÚDO EXCLUSIVO - http://tiny.cc/BPSparkle São planos de R$14 e R$20 reais e mais de 80 podcasts para apoiadores Agora há opção de pagamento anual único via Pix, Boleto ou Cartão parcelado - http://tiny.cc/BPAnual O BOLA PRESA É PARCEIRO DA KTO Receba 20% de bônus no primeiro depósito com o cupom BOLAPRESA e faça suas apostas CONHEÇA AS NOVAS ESTAMPAS DA LOJINHA BOLA PRESA NA CAPHEAD - https://www.caphead.com.br/bolapresa/ ASSINE O UOL ESPORTE CLUBE E TENHA 7 DIAS GRÁTIS DO NBA LEAGUE PASS - tiny.cc/BPUOL ... NESTE EPISÓDIO Carinha do Jabá do Subway e SALVE para os assinantes - 3:25 Como o Warriors foi campeão - 8:13 O simbolismo do título - 29:58 Momento Alura - 59:30 Adeus ao Celtics - 1:01:48 Maldição Bola Presa KTO - 1:34:40

There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

We're back to talk about the US Open, the great rounds of golf, and the legend himself, Joey Chestnut?  Don't forget to follow @Cart.Drinks on the Race to 100 Followers! We will have new swag available for the giveaway so you won't want to miss this!

On this program, President Joe Biden has been caught changing his stance on everything and I have been uncovering old audio clips to prove it. Congress sets to pass a bill to provide security for Supreme Court Justices. Some sick-o is lacing dollar bills with Fentanyl. Jeff Hardy arrested for his third DUI. Mom goes nuclear on school board. Geico pays a woman $5.2 million for getting an STD in an insured car. Texas zoo officals warn of possible chupacubra sighting. A bear has been discovered that looks like a cross between a grizzly and a polar bear. And finally, a man in Indiana was caught riding a motorized Wal-Mart cart down the freeway. -Thank you for listening!-

In this episode, Cate and Erik sit down to talk about over versus underpreparing in conversation with ADHD and the curse of all-or-nothing-thinking when it comes to *actually* getting stuff done. They discuss how planning for something big (like a new web series...) can be made even more stressful by the idea that it has to be perfectly done or not at all, and how scary it is to be on the verge of something big, especially when you never know when that hyper-fixation will wear off. Consider supporting the work we do by visiting www.patreon.com/infinitequest Erik: www.patreon.com/heygude Cate: mostlypans.com or www.patreon.com/catieosaurus Find us on TikTok and Instagram at: @catieosaurus @heygude We also stream daily on Twitch: https://www.twitch.tv/catieosaurus https://ww.twitch.tv/heygude Cool new listener email: ask@infinitequestpodcast.com Media/Business Email: infinitequestpodcast@gmail.com Find all of our links and cool stuff at: www.infinitequestpodcast.com Get your own podcast by visiting anchor.fm --- Send in a voice message: https://anchor.fm/infinitequest/message Support this podcast: https://anchor.fm/infinitequest/support